<DOC>
	<DOCNO>NCT02755337</DOCNO>
	<brief_summary>To evaluate Non-Small Cell Lung Cancer ( NSCLC ) patient clinical profile outcome treatment Gefitinib Pulmonary Oncology Outpatient Clinic Dr. Soetomo General Hospital , Surabaya , Indonesia .</brief_summary>
	<brief_title>The Evaluation Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase</brief_title>
	<detailed_description>Primary Objective : To determine efficacy Gefitinib NSCLC patient harbor positive EGFR mutation . Secondary Objective : To evaluate subjective response NSCLC patient harbor positive EGFR mutation treat Gefitinib . Safety Objective : To evaluate safety tolerability Gefitinib NSCLC patient harbor positive EGFR mutation .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>NSCLC base histopathologic examination Adenocarcinoma and/or nonadenocarcinoma base histology examination Clinical stadium stage IIIB IV Age 1670 year old Received gefitinib therapy At least complete 2 ( two ) data set RECIST 1.1 evaluation study period January 2013 July 2015 Missing data variable treatment outcomes medical record</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>non-adenocarcinoma</keyword>
</DOC>